The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience.

Pandey, Amritanshu S; Bajaj, Harpreet S; Garg, Vinay; Pandey, Avinash; Verma, Subodh

Pandey, Amritanshu S; Bajaj, Harpreet S; Garg, Vinay; Pandey, Avinash; Verma, Subodh.

Afiliación

Pandey AS; aCambridge Cardiac Care Centre, Cambridge bDepartment of Medicine, McMaster University, Hamilton cLMC Diabetes & Endocrinology, Brampton dLeadership Sinai Centre for Diabetes, Mount Sinai Hospital eDepartment of Internal Medicine, University of Toronto, Toronto fUniversity of Western Ontario, London, Ontario, Canada gCenter for Healthcare Delivery Sciences, Brigham and Women's Hospital, Harvard University Medical School, Boston, Massachusetts, USA hDivision of Cardiac Surgery, Keenan Researc

Curr Opin Cardiol ; 32(5): 633-641, 2017 Sep.

Article en En | MEDLINE | ID: mdl-28557865

Asunto(s)

Anticolesterolemiantes/uso terapéutico; Dislipidemias/tratamiento farmacológico; Proproteína Convertasa 9/uso terapéutico; Prevención Secundaria; Subtilisinas/uso terapéutico; Enfermedades Cardiovasculares; LDL-Colesterol; Humanos; Hipercolesterolemia; Factores de Riesgo; Serina Endopeptidasas

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Subtilisinas / Dislipidemias / Prevención Secundaria / Proproteína Convertasa 9 / Anticolesterolemiantes Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Curr Opin Cardiol Asunto de la revista: CARDIOLOGIA Año: 2017 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google